BMY Stock Recent News
BMY LATEST HEADLINES
On Monday, Bristol Myers Squibb & Co BMY agreed to acquire 2seventy bio, Inc. TSVT at $5.00 per share in an all-cash transaction for a total equity value of approximately $286 million, or $102 million net of estimated cash.
Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares up 76% in premarket trading on Tuesday.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all of the outstanding shares of 2seventy bio at a price of $5.00 per share in an all-cash transaction for a total equity value of approximately $286 million, or $102 million net of estimated cash. The deal represents an 88% premium to the closing price of $2.66 on March 7, 2025. “A year ago, 2seventy decided to exc.
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
On Saturday, Bristol Myers Squibb & Co BMY revealed data from the pivotal Phase 3 POETYK PsA-2 trial (IM011-055) evaluating the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA).
The EC approves BMY's combination of Opdivo and Yervoy for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.
The last time the economy experienced two negative quarters of gross domestic product was the first and second quarters of 2022, with a 1.6% pullback in the first quarter and a 0.6% decline in the second.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AAD--Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared.
Bristol Myers Squibb and Alexandria Real Estate offer strong free cash flow yields and appealing dividends, making them attractive in volatile markets. BMY's low valuation, robust drug pipeline, and cost-saving initiatives position it for potential market-beating returns. ARE benefits from strategic locations in top-tier research clusters, strong tenant demand, and resilient leasing activity, offering a high dividend yield and growth potential.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--Bristol Myers Squibb Receives European Commission Approval for Opdivo plus Yervoy for the First-Line Treatment of Adult Patients with Unresectable.